Genentech Settles FCA Suit Over Cancer Drug For $20M
A Pennsylvania federal court on Tuesday dismissed a False Claims Act suit accusing Genentech Inc. of fraudulently marketing its non-Hodgkin lymphoma drug Rituxan, after the California-based biotechnology company settled the suit...To view the full article, register now.
Already a subscriber? Click here to view full article